ILLUMINA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124 USD | -0.55% |
|
+2.43% | -10.95% |
| 12:22am | Illumina reaffirms annual revenue forecast over continued sluggish demand | RE |
| 05-02 | Illumina Q1 Non-GAAP Earnings Increase, Revenue Decreases -- Shares Down After Hours | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
124
USD
Average target price
157.5
USD
Spread / Average Target
+27.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.95% | 19.86B | |
| +7.62% | 219B | |
| +6.70% | 183B | |
| +11.94% | 132B | |
| +24.60% | 106B | |
| -2.66% | 62.09B | |
| +4.81% | 50.88B | |
| +11.55% | 50.8B | |
| -1.09% | 40.64B | |
| +26.82% | 31.59B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- Illumina : European Commission to Probe Illumina's Acquisition of Grail
